Shows
Cancer Stories: The Art of OncologyTranscription: Phone Call, 2018: A Mother’s Love in IllnessListen to Journal of Clinical Oncology's Art of Oncology poem, "Transcription: Phone Call, 2018” by Elane Kim, a student at Harvard College. The poem is followed by an interview with Kim and host Dr. Mikkael Sekeres. Kim shares her poem that lingers in the spaces between words; a mother and daughter navigating illness and memory. TRANSCRIPT Narrator: Transcription: Phone Call, 2018, by Elane Kim Spiculated mass, irregular contours. Can you come to translate these words? Something in the lung. Yes, I am eating well. Birds, green ones, are...2025-06-2419 minCancer Stories: The Art of OncologyA Whipple of Choice: Choosing Between Debilitating Surgery or Watchful WaitingListen to ASCO’s Journal of Clinical Oncology Art of Oncology article, "A Whipple of Choice” by Dr. Carl Forsberg, who is an Assistant Professor of Strategy and History at Air Force War College. The article is followed by an interview with Forsberg and host Dr. Mikkael Sekeres. Dr Forsberg shares his experience with an uncommon cancer treated by a new therapy for which no directly relevant data were available. Transcript Narrator: A Whipple of Choice, by C. W. Forsberg, PDH I sat across from a hepatobiliary surgeon on a gray October afternoon. “To be frank...2025-06-1030 minCancer Stories: The Art of OncologyAn Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last: Lessons on How NOT to Induce Coma in Your AudienceListen to ASCO’s JCO Oncology Practice, Art of Oncology Practice article, "An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last” by Dr. David Johnson, who is a clinical oncologist at University of Texas Southwestern Medical School. The article is followed by an interview with Johnson and host Dr. Mikkael Sekeres. Through humor and irony, Johnson critiques how overspecialization and poor presentation practices have eroded what was once internal medicine’s premier educational forum. Transcript Narrator: An Oncologist's Guide to Ensuring Your First Medical Grand Rounds Will Be Your Last, by David H. Joh...2025-05-1327 min
Treating Blood CancersMDS: Patient-Centered Approaches to Diagnosis and Treatment
Mikkael A. Sekeres, MD, MS, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
Recorded on April 17, 2025
Mikkael A. Sekeres, MD, MS
Chief, Division of Hematology
Professor of Medicine
Sylvester Comprehensive Cancer Center
University of Miami
Miami, FL
Join us with Dr. Mikkael Sekeres of the University of Miami Sylvester Comprehensive Cancer Center as he explores the complexities of diagnosing and treating Myelodysplastic Syndromes (MDS), including “watch and wait.” Through case-based discussion, he highlights advances in high-risk MDS management, from novel targeted therapies to stem cell transplantation and...2025-04-3042 minCancer Stories: The Art of OncologyWriting a Medical Memoir: Lessons From a Long, Steep RoadListen to ASCO’s Journal of Clinical Oncology Art of Oncology article, "Writing a Medical Memoir: Lessons From a Long, Steep Road” by David Marks, consultant at University Hospitals Bristol NHS Foundation Trust. The article is followed by an interview with Marks and host Dr. Mikkael Sekeres. Marks shares his challenging journey of writing a memoir describing his patients and career. Transcript Narrator: Writing a Medical Memoir: Lessons From a Long, Steep Road, by David Marks, PhD, MBBS, FRACP, FRCPath The purpose of this essay is to take hematologist/oncologist readers of the Journal on my ch...2025-04-2229 minCancer Stories: The Art of OncologyTamales: Celebrating a Mexican Christmas TraditionListen to ASCO’s Journal of Clinical Oncology Art of Oncology article, "Tamales” by Megan Dupuis, an Assistant Professor of Hematology and Oncology at Vanderbilt University Medical Center. The article is followed by an interview with Dupuis and host Dr. Mikkael Sekeres. Dupuis reflects on how patients invite their doctors into their culture and their world- and how this solidified her choice to be an oncologist. TRANSCRIPT Narrator: Tamales, by Megan Dupuis, MD, PhDI do not know if you know this, but tamales are an important—nay, critical—part of the Mexican Christmas traditio...2025-04-1027 minCancer Stories: The Art of OncologyThe First Hero: A Son Reflects on His Father’s IllnessListen to ASCO’s Journal of Clinical Oncology Art of Oncology poem, "The First Hero” by Christopher Kim, who is a research assistant at Institute for Stem Cell Biology and Regenerative Medicine at Stanford University. The poem is followed by an interview with Kim and host Dr. Mikkael Sekeres. Kim reflects on his post-surgery sonnet. TRANSCRIPT Narrator: The First Hero, by Christopher Kim, BS When he is like this—eyes closed, face still— he is unfamiliar. He wears a face younger than usual; fragile limbs washed in fluoresce...2025-03-2516 minCancer Stories: The Art of OncologyI Hope So Too: Creating Space to Hope with Patients and FamiliesListen to ASCO’s Journal of Clinical Oncology Art of Oncology article, "I Hope So Too” by Dr. Richard Leiter from Dana-Farber Cancer Institute. The article is followed by an interview with Leiter and host Dr. Mikkael Sekeres. Leiter shares that even in the most difficult moments, clinicians can find space to hope with patients and their families. TRANSCRIPT Narrator: I Hope So Too, by Richard E. Leiter, MD, MA “You’re always the negative one,” Carlos’ mother said through our hospital’s Spanish interpreter. “You want him to die.” Carlos was 21 yea...2025-03-1324 minCancer Stories: The Art of OncologyYou Don't Bring Me Flowers: Hospital Policy vs. Patient JoyListen to ASCO’s Journal of Clinical Oncology Art of Oncology article, "You Don't Bring Me Flowers” by Dr. Kathryn Cappell, who is an Assistant Research Physician at the National Cancer Institute. The article is followed by an interview with Cappell and host Dr. Mikkael Sekeres. Dr Cappell shares the difficulty in protecting oncology patients without taking away things that bring them joy. TRANSCRIPT Narrator: You Don’t Bring Me Flowers, by Kathryn Cappell, MD, PhD Easter morning dawned a beautiful spring day in Washington, DC. Soft sunlight and a cool breeze streamed through...2025-01-2820 minCancer Stories: The Art of OncologyHost Transition: Meet Cancer Stories New Host Dr. Mikkael SekeresWe say thank you to current Cancer Stories host, Dr. Lidia Schapira, and welcome Cancer Stories new host, Dr. Mikkael Sekeres. TRANSCRIPT Dr. Lidia Schapira: Hello and welcome to JCO's Cancer Stories: The Art of Oncology, which features essays and personal reflections from authors exploring their experience in the field of oncology. I'm your host, Dr. Lidia Schapira, a Professor of Medicine at Stanford University, and with me today is Dr. Mikkael Sekeres, who is a Professor of Medicine and the Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center in Miami. I...2025-01-1419 min
Medical Digest & Congress ReportState of the Art Treatment in Myelodysplastic Syndromes - report from ASH2024Mikkael A. Sekeres, MD, MS discusses the state of the art treatment in MDS at the 2024 ASH Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:state-art-treatment-myelodysplastic-syndromes2024-12-2005 min
Oncology Brothers: Practice-Changing Cancer DiscussionsHow to Approach to Acute Myeloid Leukemia (AML) from Community Oncology PerspectiveIn this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Mikkael Sekeres, Professor of Medicine and Chief of the Division of Hematology at the University of Miami. Together, they explore the complex landscape of acute myeloid leukemia (AML), discussing the latest advancements in diagnosis, treatment options, and risk stratification.
Key topics included:
• The importance of molecular testing in AML diagnosis and treatment planning
• The role of intensive induction chemotherapy and the classic 7+3 regimen
• New oral therapies, including FLT3 inhibitors and hypomethylating agents combined with venetoclax2024-10-1322 min
Oncology Brothers: Practice-Changing Cancer DiscussionsHow to Approach to Acute Myeloid Leukemia (AML) from Community Oncology PerspectiveIn this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Mikkael Sekeres, Professor of Medicine and Chief of the Division of Hematology at the University of Miami. Together, they explore the complex landscape of acute myeloid leukemia (AML), discussing the latest advancements in diagnosis, treatment options, and risk stratification.
Key topics included:
• The importance of molecular testing in AML diagnosis and treatment planning
• The role of intensive induction chemotherapy and the classic 7+3 regimen
• New oral therapies, including FLT3 inhibitors and hypomethylating agents combined with venetoclax2024-10-1322 min
Story in the Public SquareA Closer Look at Drugs and the FDA with Mikkael SekeresIn 2011, the Food and Drug Administration held a hearing to review a drug previously approved for the treatment of metastatic breast cancer. The hearing was fraught with concerns over the drug’s safety competing with cancer patients who felt they were alive because of the drug. Dr. Mikkael Sekeres was on the panel receiving testimony, and weighing what he heard against the long history of the FDA to make sure drugs are safe AND effective. Mikkael Sekeres is a professor of medicine and chief of the division of Hematology at the Sylvester Comprehensive Cancer Center, University of Mi...2024-07-0927 min
The HemOnc Pulse‘The HemOnc Pulse’ Live 2024: Unanswered Questions in CML TreatmentRecorded at the first “HemOnc Pulse” Live meeting in Chicago, this podcast episode features a panel discussion on unanswered questions in chronic myeloid leukemia (CML) with Elias Jabbour, MD, a Professor of Medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the University of Miami Sylvester Comprehensive Cancer Center; and Sangeetha Venugopal, MD, MS, an Assistant Professor of Medicine at the Sylvester Comprehensive Cancer Center.
2024-05-2128 minThe HemOnc Pulse"The HemOnc Pulse" Live 2024 in Chicago: AML Unanswered Questions"The HemOnc Pulse" goes on the road to Chicago with host Chadi Nabhan, MD, MBA, FACP.
This podcast episode features a panel discussion on unanswered questions in acute myeloid leukemia (AML) with Naval Daver, MD, an Associate Professor in the Department of Leukemia at the University of Texas MD Anderson Cancer Center; Sanam Loghavi, MD, of the MD Anderson Cancer Center; Rami Komrokji, MD, the Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida; and Mikkael Sekeres, MD, MS, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester...2024-05-0434 min
Live Longer WorldFDA History and Breast Cancer Drug Controversy | Dr. Mikkael SekeresDr. Mikkael Sekeres is the author of the book The Drugs and FDA. He served as the chair of the Oncology Drugs Advisory Committee of the FDA, and was on the jury for the controversial trial of the breast cancer drug Avastin.
We discuss:
- The history of the FDA,
- The trial of Avastin which got FDA approval in 2008 and revoked in 2011
- FDA's funding mechanisms
- FDA ties to big pharma
- What can be improved about the FDA and the criticisms it receives
Episode Show Notes: https://livelongerworld.com/p/msekeres
TIMESTAMPS:
0:00 Surprising finding...2024-04-241h 05Medical Digest & Congress ReportHighlights of the ASH 2023 CongressProfessor Mikkael Sekeres summarizes the most important highlights that presented at the 65th American Society of Hematology Annual Meeting.
Video: https://medicaldigest.org/scientific-contents/interview:highlights-ash-2023-congress2023-12-2109 min
Inside U Miami MedicineBlood Cancer: CAR-T Cell Therapy and Targeted TreatmentsBecause of complex genetic mutations, treating blood cancers
is particularly challenging and requires specialized therapies. In the intricate world of leukemia, lymphoma and myeloma, each breakthrough achieved through clinical trials brings scientists and clinicians a step closer to transforming standards of care for patients around the world.
Dr. Mikkael Sekeres, chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, provides insight into these diseases and shares the current research landscape in the latest episode of Inside U Miami Medicine.
2023-12-0630 minInside U Miami MedicineA cancer doctor embraces vulnerability in healing“You shouldn’t have to compromise any aspect of your humanity to be a physician.” Dr. Mikkael Sekeres, a world-renowned hematologist at Sylvester Comprehensive Cancer Center, is fighting for providers to preserve the vulnerability and humanity that initially inspired them to embark on their journey in medicine. Listen in as he and Dean Henri Ford explore important topics like physician burnout, patient communication and more on the latest episode of Inside U Miami Medicine.
2023-11-2242 min
The Smartest Doctor in the RoomEp. 120 - Can Your Cancer Diagnosis be Wrong?Dr. Mikkael Sekeres, is the chief of hematology at the University of Miami's Sylvester Comprehensive Cancer Center. We discuss his book " When Blood Breaks Down-Life Lessons from Leukemia." He gives great insight on what should you do if diagnosed with a blood cancer.2023-11-0749 min
Unbiased ScienceThe FDA: A Spoonful of Safety Makes The Medicine Go DownOn this week's episode of the pod, we are talking about a drug that's been available for decades but is suddenly being pulled from shelves: phenylephrine (something you've probably reached for when you've been congested). We bring on an expert, Dr. Mikkael Sekeres, a Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center at the University of Miami who formerly chaired the Oncologic Drugs Advisory Committee of the FDA. Dr. Sekeres helps us walk through the history of the FDA's regulation of the safety and effectiveness of drugs. We discuss some other...2023-10-2552 min
Healthcare UnfilteredASH Position on the ABIM MOC With Robert Brodsky and Mikkael SekeresChadi is joined by Dr. Robert Brodsky, President of ASH, and Dr. Mikkael Sekeres, Chair of Communications at ASH, to discuss what led to the recent ASH statement on the ABIM MOC and to gather their reactions to the ABIM response and to what next steps might look like. The guests detail the relationship and progress made between ASH and ABIM since the beginning of the partnership in 2001, the process involved for ASH to eventually release a letter related to the MOC, the contents of the letter, the ABIM’s response to the letter, and next steps needed to make pr...2023-10-241h 08
Blood Cancer TalksEpisode 22. Management of Low-Risk MDSIn this episode, we take a deep dive into low-risk MDS management. We have the privilege of being joined by the esteemed Dr. Mikkael Sekeres. We also explore his invaluable insights gained from his time at FDA ODAC and his latest literary endeavor, "Drugs and the FDA". Here are the key studies discussed:1. ASH choosing wisely: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely 2. International Consensus Classification (ICC): https://pubmed.ncbi.nlm.nih.gov/35767897/ 3. WHO classification 2022: https://pubmed.ncbi.nlm.nih.gov/35732829/ 4. I...2023-05-201h 03
New Books in MedicinePharmacological Histories Ep. 2: Mikkael A. Sekeres on the Drugs Fighting LeukemiaThis episode offers an insight into the work of leading cancer specialist and author of When Blood Breaks Down, Mikkael A. Sekeres. 1 in 2 people will develop cancer in their lifetime, but thankfully treatment for the disease is rapidly changing and improving. I ask Mikkael about the drugs that allow people to beat cancer and live better with it.When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together an...2023-05-1133 min
New Books in Biology and EvolutionPharmacological Histories Ep. 2: Mikkael A. Sekeres on the Drugs Fighting LeukemiaThis episode offers an insight into the work of leading cancer specialist and author of When Blood Breaks Down, Mikkael A. Sekeres. 1 in 2 people will develop cancer in their lifetime, but thankfully treatment for the disease is rapidly changing and improving. I ask Mikkael about the drugs that allow people to beat cancer and live better with it.When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together an...2023-05-0933 min
New Books in SciencePharmacological Histories Ep. 2: Mikkael A. Sekeres on the Drugs Fighting LeukemiaThis episode offers an insight into the work of leading cancer specialist and author of When Blood Breaks Down, Mikkael A. Sekeres. 1 in 2 people will develop cancer in their lifetime, but thankfully treatment for the disease is rapidly changing and improving. I ask Mikkael about the drugs that allow people to beat cancer and live better with it.When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together an...2023-05-0933 min
The MIT Press PodcastPharmacological Histories Ep. 2: Mikkael A. Sekeres on the Drugs Fighting LeukemiaThis episode offers an insight into the work of leading cancer specialist and author of When Blood Breaks Down, Mikkael A. Sekeres. 1 in 2 people will develop cancer in their lifetime, but thankfully treatment for the disease is rapidly changing and improving. I ask Mikkael about the drugs that allow people to beat cancer and live better with it.When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together an...2023-05-0933 min
the Essential Free Audiobooks in Non-Fiction, Current Affairs, Law, & PoliticsDrugs and the FDA: Safety, Efficacy, and the Public's Trust by Mikkael A. SekeresPlease visit https://thebookvoice.com/podcasts/1/audiobook/649571 to listen full audiobooks. Title: Drugs and the FDA: Safety, Efficacy, and the Public's Trust Author: Mikkael A. Sekeres Narrator: Mike Lenz Format: Unabridged Audiobook Length: 8 hours 40 minutes Release date: April 11, 2023 Genres: Current Affairs, Law, & Politics Publisher's Summary: Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and fo...2023-04-1130 min
Grab the Essential Full Audiobooks in Non-Fiction, Current Affairs, Law, & PoliticsDrugs and the FDA: Safety, Efficacy, and the Public's Trust by Mikkael A. SekeresPlease visithttps://thebookvoice.com/podcasts/1/audiobook/649571to listen full audiobooks.
Title: Drugs and the FDA: Safety, Efficacy, and the Public's Trust
Author: Mikkael A. Sekeres
Narrator: Mike Lenz
Format: Unabridged Audiobook
Length: 8 hours 40 minutes
Release date: April 11, 2023
Genres: Current Affairs, Law, & Politics
Publisher's Summary:
Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres—a leading oncologist and former ch...2023-04-118h 40
Healthcare Unfiltered“Toxic Exposure” Review With Kelly Ryerson and Mikkael SekeresIn a change-of-pace episode, Chadi has the tables turned on him as he is interviewed by two supporters and reviewers of his new book “Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice.” Kelly Ryerson, MBA, GlyphosateGirl.com, and Mikkael Sekeres, author of “Drugs and the FDA: Safety, Efficacy, and the Public's Trust” and “When Blood Breaks Down: Life Lessons from Leukemia,” ask Chadi to comment on why he was chosen as an expert witness, how glyphosate causes cancer and how much exposure is needed to cause lymphoma, why Roundup is able to stay on the market t...2023-04-0456 min
This is DemocracyThis is Democracy – Episode 232: FDA and Public HealthMikkael Sekeres is a Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine. Dr. Sekeres has published hundreds of scholarly and Op-Ed articles, and he is the author of 8 books, including: When Blood Breaks Down: Life Lessons from Leukemia (The MIT Press 2020) and most recently, Drugs and the FDA: Safety, Efficacy, and the Public’s Trust (The MIT Press 2022).2023-03-3034 min
The PQI PodcastSeason 4, Ep. 1 : Drugs and the FDA with Dr. Mikkael SekeresSeason 4 Episode 1- Drugs and the FDA with Dr. Mikkael Sekeres This week we sit down with Dr. Mikkael Sekeres to discuss his latest book Drugs and the FDA. Dr. Sekeres is Professor of Medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, and former Chair of the Oncologic Drugs Advisory Committee of the FDA. A regular contributor to the Well section of the New York Times, he is the author of When Blood Breaks Down: Life Lessons from Leukemia (MIT Press). More i...2023-01-1938 min
The DemystifySci PodcastDeath, Drugs, & Corruption at the FDA - Dr. Mikkael Sekeres, University of MiamiWhat happens when the FDA approves a drug that doesn't work? Say it gets accelerated approval from the regulatory body, but further clinical trials demonstrate a lack of efficacy. Normally, the agency requests that the company take their drug off the market, the company does so, and so the wheel turns. But when post-approval clinical trials showed that Genentech's blockbuster breast cancer drug Avastin was killing women, the company broke with more than a century of tradition, and declined to take their drug off the market. We talk with Miami University's Mikkael Sekeres about his experience sitting on the...2023-01-122h 04
Book Society@MikkaelSekeres and I talk about the fascinating history of the Food and Drug Administration and how Vaccines, i.e. COVID, get approved quickly.Dr. Mikkael Sekeres and I talk about the fascinating history of the Food and Drug Administration and how Vaccines, i.e. COVID, get approved quickly. We also talk about how billions of dollars and regulatory loopholes can result in ineffective drugs staying on the market. We also talk about what people do when they find out they have cancer.Buy Drugs and the FDA:https://www.amazon.com/Drugs-FDA-Safety-Efficacy-Publics/dp/0262047314/ref=sr_1_1?crid=2MK66OVU81U71&keywords=drugs+and+the+fda&qid=1670615780&sprefix=drugs+and+the+fda%2Caps%2C124&sr=8-1Here's a re...2022-12-0936 min
Book Society@MikkaelSekeres and I discuss The Brief And Wondrous Life of Oscar WaoDr. Mikkael Sekeres can talk at length about ideas and literature. He can also cure cancer.2022-12-0223 min
Living Legacy LeadershipDrugs and the FDA Safety, Efficacy & The Public Trust- Miami Book Fair author Dr. Mikkael SekeresDrugs and the FDA: Safety, Efficacy & The Public Trust- Miami Book Fair author Dr. Mikkael Sekeres
Mikkael Sikeres, a respected cancer specialist, professor, author and former chair of the FDA’s drug advisory committee, explores the Food and Drug Administration’s mission, global health crises, patient advocates and politics of the pharmaceutical industry today. While this book primarily tackles the case of the drug Avastin used to treat breast cancer patients, he also covers some inbuilt conflicts of interest between demands for protecting patients and speed of offering potential treatments. Join us to hear if Dr. S...2022-11-0726 min
New Books in Drugs, Addiction and RecoveryMikkael A. Sekeres, "Drugs and the FDA: Safety, Efficacy, and the Public's Trust" (MIT Press, 2022)How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA: Safety, Efficacy, and the Public's Trust (MIT Press, 2022), Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the st...2022-11-0456 min
New Books in MedicineMikkael A. Sekeres, "Drugs and the FDA: Safety, Efficacy, and the Public's Trust" (MIT Press, 2022)How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA: Safety, Efficacy, and the Public's Trust (MIT Press, 2022), Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the st...2022-11-0458 min
The MIT Press PodcastMikkael A. Sekeres, "Drugs and the FDA: Safety, Efficacy, and the Public's Trust" (MIT Press, 2022)How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA: Safety, Efficacy, and the Public's Trust (MIT Press, 2022), Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the st...2022-11-0456 min
New Books in Public PolicyMikkael A. Sekeres, "Drugs and the FDA: Safety, Efficacy, and the Public's Trust" (MIT Press, 2022)How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA: Safety, Efficacy, and the Public's Trust (MIT Press, 2022), Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the st...2022-11-0458 min
New Books in American PoliticsMikkael A. Sekeres, "Drugs and the FDA: Safety, Efficacy, and the Public's Trust" (MIT Press, 2022)How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA: Safety, Efficacy, and the Public's Trust (MIT Press, 2022), Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the st...2022-11-0458 min
New Books In Public HealthMikkael A. Sekeres, "Drugs and the FDA: Safety, Efficacy, and the Public's Trust" (MIT Press, 2022)How the FDA was shaped by public health crises and patient advocacy, told against a background of the contentious hearings on the breast cancer drug Avastin.Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate US authority on a drug's safety and efficacy? In Drugs and the FDA: Safety, Efficacy, and the Public's Trust (MIT Press, 2022), Mikkael Sekeres--a leading oncologist and former chair of the FDA's cancer drug advisory committee--tells the st...2022-11-0458 min
Seize the Moment PodcastMikkael Sekeres - Big Pharma vs the FDA - The Avastin Trial | STM Podcast #150On episode 150, we welcome Dr. Mikkael Sekeres to discuss the social and political climate that fostered the necessity to create the FDA, medical charlatans and the history of pseudo-medicine, the necessity of clinical trials for creating safe and effective medications, why anecdotal evidence isn’t equivalent to scientific validation, the FDA’s decision to remove the breast cancer indication for the drug Avastin and Genentech’s decision to fight it, Mikkael’s personal experience during that hearing while a member of the jury, the public’s distrust of the FDA and where it stems from, Genentech spin-doctoring data to make their...2022-10-301h 05
The Podcast by KevinMDWhen patients want their doctors to heal"I think it’s much more likely that my patients — some of whom are terminal and facing their own mortality; others who are suffering through a multitude of side effects from their cancers or our treatments – my beautiful patients haven’t let cancer compromise that core of humanity that allows them to care deeply about the welfare of another human being, despite what they are living through. They wanted me to heal just as much as I hoped for the same for them." Mikkael A. Sekeres is a hematology-oncology physician and author of Drugs and the FDA: Safety, Ef...2022-10-2815 min
Healthcare UnfilteredDrugs and the FDA: A New Book With Mikkael SekeresRecurring guest Mikkael A. Sekeres, MD, Professor of Medicine and Chief of the Division of Hematology, Sylvester Comprehensive Cancer Center, is today’s guest of honor to discuss and spotlight his just-published book: Drugs and the FDA: Safety, Efficacy, and the Public's Trust. Dr. Sekeres begins by sharing an anecdote of his experience on the FDA Oncologic Drugs Advisory Committee (ODAC) for Avastin as an inspiration to write the book. Then, he delves into the detailed process of becoming an ODAC member and how conflicts of interest are handled in the screening process, how personal experience bias (rather than data) ma...2022-10-041h 08
The Readout Loud228: A surprise success in Alzheimer's and how FDA history seeded modern controversyLecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising development and its sweeping implications. Then, oncologist Mikkael Sekeres joins us to talk about his new book, which is a history of the FDA and an insider’s look at one of the agency’s most contentious drug approval hearings.2022-09-2935 min
JAMA Clinical ReviewsDiagnosis and Management of Myelodysplastic SyndromesMyelodysplastic neoplasms, or myelodysplastic syndromes, are diagnosed in approximately 4 of 100 000 people each year in the US and are associated with a 5-year survival rate of approximately 37%. In this JAMA podcast and author interview, JAMA Deputy Editor Mary M. McDermott, MD, discusses the diagnosis and treatment of myelodysplastic syndromes with Mikkael A. Sekeres, MD, MS, chief of hematology and professor of medicine of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. Related Content: Diagnosis and Treatment of Myelodysplastic Syndromes2022-09-0622 min
HCPLive PodcastsRare Disease Report: Myelodysplastic Syndromes & Acute Myeloid LeukemiaMikkael Sekeres, MD, is no stranger to rare disease. In his own words, there are rare diseases and then there are very rare diseases. Sickle cell is a rare condition with an incidence rate of just over 100 per 100,000 people. Sekeres focuses much of his treatment on patients with bone marrow disorders like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). These conditions have an incidence rate of approximately 5 per 100,000.
In this episode he shares insight on treatment practices, clinical trial procedures and hurdles, as well as the importance of finding reliable sources for information.2022-06-0322 minLiving Legacy LeadershipSeeing Spirit, Utter Humanity & God in his Blood Cancer Patients: by Miami Book Fair Author Mikkael SekeresSeeing Spirit, Utter Humanity & God in his Blood Cancer Patients: by Miami Book Fair Author Mikkael Sekeres
In his celebrated book, When Blood Breaks Down: Life Lessons from Leukemia, Mikkael Sekeres tells the compelling stories of three people who receive diagnoses of adult leukemia within hours of each other. We join the intimacy of the conversations Sekeres has with his patients and listen in as he teaches trainees. Along the way, he also explores leukemia in its different and complex forms as well as the development of drugs to treat it - describing, among many...2021-11-1527 min
Taking A Leap -- Deborah BrownMiami Book Fair Author of "When Blood Breaks Down: Life Lessons from Leukemia"Miami Book Fair Author of "When Blood Breaks Down: Life Lessons from Leukemia"
Dr. Mikkael A. Sekeres joined the University of Miami Health System and Sylvester Comprehensive Cancer Center as Chief of the Division of Hematology with a focus on Leukemia and Myeloid Disorders. He earned his medical degree and a Master’s Degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana Farber Cancer Instit...2021-11-1023 minTaking A Leap -- Deborah BrownMiami Book Fair Author of "When Blood Breaks Down: Life Lessons from Leukemia"Miami Book Fair Author of "When Blood Breaks Down: Life Lessons from Leukemia"
Dr. Mikkael A. Sekeres joined the University of Miami Health System and Sylvester Comprehensive Cancer Center as Chief of the Division of Hematology with a focus on Leukemia and Myeloid Disorders. He earned his medical degree and a Master’s Degree in clinical epidemiology from the University of Pennsylvania School of Medicine. Dr. Sekeres completed his postgraduate training at Harvard University, finishing an internal medicine residency at Massachusetts General Hospital and a fellowship in hematology-oncology at the Dana Farber Cancer Instit...2021-10-1123 min
Beyond the Journal (Audio)Dr. Mikkael Sekeres, on the Adventures of a Midcareer Move and the Art of the Clinical Narrative | BTJ-023Dr. Mikkael Sekeres of Univ of Miami chats with Charu Aggarwal and Jack West about challenges and opportunities with his move from Cleveland to Miami, his commitment to writing for a broad audience, & challenges for MDs & patients in the wake of COVID-19.2021-09-2146 min
Healthcare UnfilteredMid-Career Academic Transitions with Mikkael Sekeres and David SteensmaMikkael Sekeres (@MikkaelSekeres), MD, chief of the division of hematology at the University of Miami Sylvester Comprehensive Cancer Center, and David Steensma (@DavidSteensma), MD, global hematology head at Novartis, share their recent experiences undergoing career transitions. The physicians dive into a discussion on how often fellowships are given to candidates who are pursuing academic careers, how and why the decisions were made to leave one institution for another (or an institution for industry), whether or not to interview for new positions discreetly, how to approach negotiating aspects of a new employment contract, and so much more.
Read Dr. Sekeres' narrative...2021-09-141h 14
Beyond the JournalDr. Mikkael Sekeres, on the Adventures of a Midcareer Move and the Art of the Clinical Narrative | BTJ-023Dr. Mikkael Sekeres of Univ of Miami chats with Charu Aggarwal and Jack West about challenges and opportunities with his move from Cleveland to Miami, his commitment to writing for a broad audience, & challenges for MDs & patients in the wake of COVID-19.2021-09-1446 min
CMEA Novel Therapeutic Approach in Myeloid Malignancies: Targeting the Neddylation Pathway
Host: Jennifer Caudle, DO
Guest: Mikkael A. Sekeres, MD, MS
Guest: Sara M. Tinsley, PhD, ARNP, AOCNP
Please note: This activity is no longer available for continuing education credit. There is a lack of available therapeutic options for the management of patients with myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Novel therapeutic approaches are being evaluated, particularly those that target the NEDD8-activating enzyme (NAE). Evaluating the rationale for NAE inhibition, assessing emerging safety and efficacy data on use of NAE inhibitors in myeloid malignancies, and...2021-08-3100 min
New Books in ScienceMikkael A. Sekeres, "When Blood Breaks Down: Life Lessons from Leukemia" (MIT Press, 2020)When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzle of bone marrow gone wrong. The two of you are in it together. In When Blood Breaks Down: Life Lessons from Leukemia (MIT Press, 2020), Mikkael Sekeres, a leading cancer specialist, takes readers on the journey that patient and doctor travel together....2021-08-161h 00New Books in MedicineMikkael A. Sekeres, "When Blood Breaks Down: Life Lessons from Leukemia" (MIT Press, 2020)When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzle of bone marrow gone wrong. The two of you are in it together. In When Blood Breaks Down: Life Lessons from Leukemia (MIT Press, 2020), Mikkael Sekeres, a leading cancer specialist, takes readers on the journey that patient and doctor travel together....2021-08-161h 00
New Books in Biology and EvolutionMikkael A. Sekeres, "When Blood Breaks Down: Life Lessons from Leukemia" (MIT Press, 2020)When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzle of bone marrow gone wrong. The two of you are in it together. In When Blood Breaks Down: Life Lessons from Leukemia (MIT Press, 2020), Mikkael Sekeres, a leading cancer specialist, takes readers on the journey that patient and doctor travel together....2021-08-161h 00Cancer Stories: The Art of OncologyTrying To Remember How We Saw Patients on That April MorningIn "Trying To Remember How We Saw Patients on That April Morning" by Mikkael Sekeres, an oncologist reflects on virtual visits during the COVID-19 pandemic. TRANSCRIPT SPEAKER 1: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. 2021-03-2224 min
VJHemOnc PodcastThe MDS sessions: clinical trial participation, endpoints & approvalsMyelodysplastic syndromes (MDS) represent a range of disorders characterized by morphologic dysplasia, cytopenias, and a risk of progression to acute myeloid leukemia. With hematopoietic stem cell transplantation representing the only curative option for patients with MDS, the field has not seen the rapid evolution in treatments witnessed in other hematological malignancies.
In this podcast, Amer Zeidan, MBBS, Yale University, and Yale Cancer Center, New Haven, CT, chairs a discussion evaluating issues pertaining to MDS, from clinical trial designs to the latest understanding of disease biology as well as future outlooks. Dr Zeidan is joined by Amy DeZern...2020-11-1744 min
Download Top Free Audiobooks in Biography & Memoir, History & CultureWhen Blood Breaks Down: Life Lessons from Leukemia by Mikkael A. SekeresPlease visit https://thebookvoice.com/podcasts/1/audiobook/430151 to listen full audiobooks. Title: When Blood Breaks Down: Life Lessons from Leukemia Author: Mikkael A. Sekeres Narrator: Mike Lenz Format: Unabridged Audiobook Length: 7 hours 28 minutes Release date: July 7, 2020 Ratings: Ratings of Book: 5 of Total 1 Genres: History & Culture Publisher's Summary: When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to...2020-07-0730 min
Access Top-Rated Free Audiobooks in Biography & Memoir, MemoirsWhen Blood Breaks Down: Life Lessons from Leukemia by Mikkael A. SekeresPlease visit https://thebookvoice.com/podcasts/1/audiobook/430151 to listen full audiobooks. Title: When Blood Breaks Down: Life Lessons from Leukemia Author: Mikkael A. Sekeres Narrator: Mike Lenz Format: Unabridged Audiobook Length: 7 hours 28 minutes Release date: July 7, 2020 Ratings: Ratings of Book: 5 of Total 1 Genres: Memoirs Publisher's Summary: When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve...2020-07-0730 min
Access Top-Rated Full Audiobooks in Biography & Memoir, MemoirsWhen Blood Breaks Down: Life Lessons from Leukemia by Mikkael A. SekeresPlease visithttps://thebookvoice.com/podcasts/1/audiobook/430151to listen full audiobooks.
Title: When Blood Breaks Down: Life Lessons from Leukemia
Author: Mikkael A. Sekeres
Narrator: Mike Lenz
Format: Unabridged Audiobook
Length: 7 hours 28 minutes
Release date: July 7, 2020
Ratings: Ratings of Book: 5 of Total 1
Genres: Memoirs
Publisher's Summary:
When you are told that you have leukemia, your world stops. Your brain can't function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the...2020-07-077h 28
The HematologistWhat to Expect at the 60th ASH Annual Meeting With Drs. Hamadani, Sekeres, and Sola-VisnerIn this podcast, 2018 ASH News Daily Editor-in-Chief Dr. Mehdi Hamadani has a conversation with Education Program Co-chair Dr. Mikkael Sekeres and Scientific Program Co-chair Dr. Martha Sola-Visner about what to expect at the 60th ASH Annual Meeting and Exposition, taking place December 1-4, 2018, in San Diego, California. They talk about stimulating sessions to look forward to, new exciting features and features from previous years that are making their return such as Alexa-Ask ASH and Collaboration Rooms, as well as an array of networking events. Attendees will have the opportunity to connect with the top minds in the field of malignant...2018-11-2127 min
Download Audiobook in Newspapers & Magazines, News & CultureInformed Patient? Dont Bet On It by Mikkael A. Sekeres | Free AudiobookListen to full audiobooks for free on :https://hotaudiobook.com/freeTitle: Informed Patient? Dont Bet On It
Author: Mikkael A. Sekeres, M.D., Timothy D. Gilligan, M.D.
Narrator: Fleet Cooper
Format: Unabridged
Length: 6 mins
Language: English
Release date: 03-08-17
Publisher: The New York Times
Genres: Newspapers & Magazines, News & Culture
Summary:
The secret is that informed consent in health care is commonly not-so-well informed. It might be a document we ask you to sign, at the behest of our lawyers, in case we end up in court if a bad outcome happens. Unfortunately, it is often not really about...2017-03-0806 min
Frankly Speaking About Cancer with the Cancer Support CommunityEncore: The Art and Science of Medicine: A Conversation with Dr. Mikkael SekeresHippocrates, the Greek physician who is revered as the father of medicine, said, “The art has three factors: the disease, the patient, the physician.” On this episode of Frankly Speaking About Cancer guest host Linda House takes a look at the physician experience—the changing landscape in which they practice, the challenges they face as well as their hopes and aspirations for the future. Linda is joined by Dr. Mikkael Sekeres whose NY Times and Huffington Post blogs aim to shed light on just that.2016-07-1255 min
Frankly Speaking About CancerEncore: The Art and Science of Medicine: A Conversation with Dr. Mikkael SekeresHippocrates, the Greek physician who is revered as the father of medicine, said, “The art has three factors: the disease, the patient, the physician.”2016-07-1255 minFrankly Speaking About Cancer with the Cancer Support CommunityThe Art and Science of Medicine: A Conversation with Dr. Mikkael SekeresHippocrates, the Greek physician who is revered as the father of medicine, said, “The art has three factors: the disease, the patient, the physician.” On this episode of Frankly Speaking About Cancer guest host Linda House takes a look at the physician experience—the changing landscape in which they practice, the challenges they face as well as their hopes and aspirations for the future. Linda is joined by Dr. Mikkael Sekeres whose NY Times and Huffington Post blogs aim to shed light on just that.2016-05-0355 minFrankly Speaking About CancerThe Art and Science of Medicine: A Conversation with Dr. Mikkael SekeresHippocrates, the Greek physician who is revered as the father of medicine, said, “The art has three factors: the disease, the patient, the physician.”2016-05-0355 min
Oncology Times - OncTimes TalkA Clinical Research Consortium for MDSMikkael A. Sekeres, MD, MS—who’s co-chairing the unique initiative to bolster research for the rare disease—explains what’s on the agenda and who’s involved.
Hear what he told OT about the $16-million, five-year plan.2013-08-0704 minOncology Times - OncTimes TalkOT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MSDr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and acute myelogenous leukemia, including the overlaps between the two in older adults, new opportunities to better define MDS epidemiologically in the US, and new treatment approaches.2010-04-0912 min
OT Broadcast NewsOT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MSDr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and acute myelogenous leukemia, including the overlaps between the two in older adults, new opportunities to better define MDS epidemiologically in the US, and new treatment approaches.2010-04-0900 min
Unlock a Library in Your Pocket With Full AudiobookDrugs and the FDA: Safety, Efficacy, and the Public's Trust Audiobook by Mikkael A. SekeresListen to this audiobook in full for free onhttps://hotaudiobook.com/freeID: 649571
Title: Drugs and the FDA: Safety, Efficacy, and the Public's Trust
Author: Mikkael A. Sekeres
Narrator: Mike Lenz
Format: Unabridged
Length: 08:40:03
Language: English
Release date: 04-11-23
Publisher: Tantor Media
Genres: Non-Fiction, Politics, Law, Public Policy
Summary:
Food and Drug Administration approval for COVID-19 vaccines and the controversial Alzheimer's drug Aduhelm made headlines, but few of us know much about how the agency does its work. Why is the FDA the ultimate United States authority on a drug's safety and efficacy? In Drugs and the FDA, Mikkael Sekeres-a...1970-01-018h 40